Status:
UNKNOWN
Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience
Lead Sponsor:
Mansoura University
Conditions:
Pneumonia, Viral
Eligibility:
All Genders
18+ years
Brief Summary
COVID-19 is a respiratory disease caused by a new coronavirus (SARS-CoV-2) and causes significant morbidity and mortality. This study is a retrospective trial to assess the efficacy of Remdesivir in a...
Detailed Description
COVID-19 is a novel respiratory disease caused by coronavirus (SARS-CoV-2) and results in significant morbidity and mortality. To date there is no approved medication for the treatment of patients wit...
Eligibility Criteria
Inclusion
- Adult ≥ 18 years old.
- SARS-CoV-2 infection confirmed.
- Patients having classical radiological lesions of COVID-19 on X-ray chest or HRCT chest.
- Hospitalized patients who received at least one administration of Remdesivir therapy (Dose: 200mg day one then 100mg daily for up to 10 days).
Exclusion
- Presences of chronic renal failure \> 4 stage, GFR \< 30ml/min.
- ALT/AST \> 5 times than normal values.
- Pregnant women.
Key Trial Info
Start Date :
January 26 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04728880
Start Date
January 26 2021
End Date
May 30 2021
Last Update
January 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Hospital
Al Mansurah, Dakahliya, Egypt, 35511